Actinidia arguta stem source volatile active ingredient extract and application thereof
By extracting volatile components from the stems of the hardy kiwifruit, and using headspace solid-phase microextraction technology with sodium chloride salting-out and a DVB/CAR/PDMS three-phase extraction head, an effective α-glucosidase inhibitor and insulin sensitizer were prepared. This solved the problems of side effects of existing drugs and untapped volatile components, and achieved a significant hypoglycemic effect.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- YULIN CITY SECOND HOSPITAL (CITY ORTHOPEDIC HOSPITAL)
- Filing Date
- 2026-04-07
- Publication Date
- 2026-05-12
AI Technical Summary
Existing medications for treating type 2 diabetes have issues such as gastrointestinal reactions, weight gain, risk of hypoglycemia, and drug resistance. Furthermore, current research mainly focuses on non-volatile components, failing to fully explore the potential of volatile components.
Volatile active ingredients, including trans-3-hexen-1-ol and 1-hexanol, were extracted from the stems of Actinidia arguta using headspace solid-phase microextraction technology with sodium chloride salting-out combined with a DVB/CAR/PDMS three-phase extraction head. These ingredients were used to prepare insulin sensitizers and α-glucosidase inhibitors.
The extract significantly inhibited α-glucosidase (IC50: 0.43 mg/mL), promoted glucose consumption and glycogen synthesis in insulin-resistant hepatocytes, improved insulin resistance, lowered blood glucose, and had no significant cytotoxicity.
Smart Images
Figure CN122005633A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of component extraction technology, specifically relating to an extract of volatile active ingredients from the stem of Actinidia arguta and its application. Background Technology
[0002] Diabetes, especially type 2 diabetes, has a core pathological mechanism rooted in insulin resistance, a decreased sensitivity of the body to insulin leading to impaired blood glucose regulation. Current first-line treatments include biguanides, sulfonylureas, and insulin sensitizers. While these are effective in controlling blood sugar, long-term use often results in side effects such as gastrointestinal reactions, weight gain, risk of hypoglycemia, and liver and kidney damage. Furthermore, some drugs exhibit drug resistance. Therefore, developing novel, highly effective, and low-toxicity insulin sensitizers and alpha-glucosidase inhibitors targeting new targets with novel mechanisms of action, particularly those derived from natural products, has become a crucial direction in current drug development.
[0003] Soft-fleshed kiwifruit ( Actinidia arguta (Siebold & Zucc.) Planch. ex Miq.), as a plant used for both food and medicine, has long been recorded in traditional Chinese medicine for its medicinal value. Its stem is sour, astringent, and neutral in nature, possessing the effects of clearing heat and detoxifying, promoting diuresis, strengthening the stomach and replenishing deficiency. It is often used for chronic hepatitis, as an adjunct treatment for cancer, and for treating injuries from falls and blows. Preliminary modern pharmacological studies have confirmed that its rich flavonoids, triterpenoids, and phenolic acids (non-volatile components) contribute significantly to its anti-tumor, anti-inflammatory, antioxidant, and immune-enhancing activities. Previous studies have found that its non-volatile extracts show clear anti-diabetic potential, laying the foundation for the development of stem resources. However, these studies on non-volatile extracts have focused on highly polar components extracted using water or organic solvents. It is worth noting that plant volatile organic compounds (VOCs) are not only characteristic flavor substances but also an important resource of bioactive compounds. Therefore, further research and development of its volatile components is needed. Summary of the Invention
[0004] To address the aforementioned problems, this invention provides an extract of volatile active ingredients from the stems of Actinidia arguta and its applications.
[0005] The first aspect of this invention provides an extract of volatile active ingredients from the stem of *Actinidia arguta* with anti-diabetic effects. This extract is obtained by releasing the volatile active ingredients from the *Actinidia arguta* stem through sodium chloride salting-out, followed by headspace solid-phase microextraction using a DVB / CAR / PDMS three-phase extraction head. The diameter of the DVB / CAR / PDMS three-phase extraction head is 50 / 30 μm. The mass ratio of sodium chloride to the *Actinidia arguta* stem is 1-4:1-3; preferably, the mass ratio is 2:1.5. Based on the principle of salting-out, the effect of sodium chloride aqueous solution in enhancing the release of volatile components ceases after near saturation; excessive solid sodium chloride may adsorb the target components, inhibiting their release into the headspace and potentially damaging the analytical instrument. Therefore, controlling the mass ratio of sodium chloride to the stem within the range of 1-4:1-3 ensures the synergistic effect of salting-out while avoiding adverse effects.
[0006] The headspace solid-phase microextraction was performed at a temperature of 50℃~60℃ for 60min~70min.
[0007] In another preferred embodiment, the relative content of trans-3-hexen-1-ol and the relative content of 1-hexanol in the extract of volatile active ingredients from the stem of Actinidia arguta is 50.11%.
[0008] In another preferred embodiment, the hardy kiwifruit stem source refers to a sample obtained by quick-freezing and grinding the stem source sample with liquid nitrogen to obtain a particle size ≤1mm. This treatment embrittles the fibrous tissue, increases the specific surface area, and promotes the release of volatile components.
[0009] In another preferred embodiment, the stem source has a moisture content of 70% to 80%, which means it is a fresh stem source with high moisture content.
[0010] A second aspect of this invention provides the application of the extract of volatile active ingredients from the stem of *Actinidia arguta* in the preparation of a medicament for alleviating and improving insulin resistance. The improvement of insulin resistance includes promoting glucose consumption and increasing glycogen synthesis in an insulin-resistant hepatocyte model.
[0011] In another preferred embodiment, the content of the extract of volatile active ingredients from the stem of Actinidia arguta in the drug is 100 μg / mL.
[0012] A second aspect of this invention provides the use of the extract of volatile active components from the stem of *Actinidia arguta* in the preparation of a drug that inhibits α-glucosidase. The inhibition of α-glucosidase includes the inhibition of carbohydrate digestion.
[0013] In another preferred embodiment, the content of the extract of volatile active ingredients from the stem of Actinidia arguta in the drug is not less than 1 mg / mL.
[0014] In another preferred embodiment, the volatile active ingredient extract from the stem of *Actinidia arguta* is desorbed into a solvent to obtain an eluent; or the drug is obtained by adsorbing the volatile active ingredient extract from the stem of *Actinidia arguta* onto a carrier. The solvent is any one of ethanol, propylene glycol, polyethylene glycol 400, and dimethyl sulfoxide; the carrier is any one of ZIF-8, porous starch, β-cyclodextrin, α-cyclodextrin, γ-cyclodextrin, and macroporous adsorption resin.
[0015] Compared with the prior art, the present invention has the following beneficial effects: This invention utilizes sodium chloride salting-out to release volatile active components from the stems of *Actinidia arguta*, and then uses headspace solid-phase microextraction to obtain an extract of these volatile active components. Experiments have shown that this extract exhibits significant α-glucosidase inhibitory activity, IC50... 50 At a concentration of 0.43 mg / mL, it exhibits insulin-sensitizing effects and significantly promotes glucose consumption and glycogen synthesis in IR-L02 cells at a concentration of 100 μg / mL. Furthermore, this extract can exert its hypoglycemic effect through a dual mechanism of inhibiting carbohydrate absorption and improving peripheral insulin sensitivity, demonstrating the potential for synergistic effects.
[0016] The active ingredients in the volatile active ingredient extract from the stems of the hardy kiwifruit of this invention are trans-3-hexen-1-ol and 1-hexanol, wherein the relative content of trans-3-hexen-1-ol is 50.11% and the relative content of 1-hexanol is 28.39%. This invention provides a clear direction for the high-value development of hardy kiwifruit stem waste, realizing the transformation from agricultural waste to pharmaceutical raw materials. Attached Figure Description
[0017] Figure 1 Total ion chromatogram of volatile components in the stem of the hardy kiwifruit.
[0018] Figure 2 The figure shows the inhibition rate of α-glucosidase by extracts of volatile components from the stems of Actinidia arguta.
[0019] Figure 3 The figure shows the effect of extracts of volatile components from the stems of Actinidia arguta on the viability of L02 cells.
[0020] Figure 4 The figure shows the effect of different concentrations of insulin on glucose consumption in L02 cells.
[0021] Figure 5The figure shows the effect of extracts of volatile components from the stems of Actinidia arguta on glucose consumption by IR-L02.
[0022] Figure 6 The figure shows the effect of extracts of volatile components from the stems of Actinidia arguta on the synthesis of liver glycogen by IR-L02. Detailed Implementation
[0023] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention.
[0024] Unless otherwise specified, the experimental methods described in the following embodiments are conventional methods; unless otherwise specified, the reagents and materials are commercially available.
[0025] Example 1: Preparation of volatile component extracts from the stems of Actinidia arguta (hardy kiwifruit) Identification and characterization of extracts To accurately reveal the compositional characteristics of volatile components derived from the stems of the hardy kiwifruit, this invention employs a headspace solid-phase microextraction-gas chromatography-mass spectrometry (HS-SPME-GC-MS) analytical system optimized for its high moisture content and dense fibrous matrix. Key optimization points are as follows:
[0026] (1) Targeted sample pretreatment and extraction optimization Sample pretreatment: Fresh stem samples were quick-frozen and ground in liquid nitrogen to a particle size ≤1mm to embrittle the fibrous tissue, increase the specific surface area, and promote the release of volatile components.
[0027] Enhanced salting-out: Targeting the high moisture content of stems (70%~80%), 2g of anhydrous sodium chloride and 1.5g of sample were added to the headspace vial. The salting-out effect effectively broke the hydrogen bonds between volatile components and water molecules, solving the problem of insufficient release of components due to water encapsulation in conventional methods. Comparative experiments (using an equal amount of sample without added salting-out agent as a control) verified that this optimization improved the efficiency of component migration to the headspace by more than 40%.
[0028] Fully polar extraction: Employing a 50 / 30μm DVB / CAR / PDMS three-phase extraction head, its coating encompasses neutral, polar, and non-polar components, superior to single-coating methods, enabling comprehensive capture of volatile components of varying polarities, including alcohols, esters, terpenes, and alkanes, from the stem. DVB / CAR / PDMS stands for divinylbenzene / carboxyl / polydimethylsiloxane.
[0029] Mild extraction parameters: The extraction temperature was set at 55℃ for 60 min to obtain volatile component extracts from the stems of Actinidia arguta. This mild temperature condition was designed to avoid the decomposition of heat-sensitive terpenes in the stems, such as linalool and D-limonene, at excessively high temperatures (>65℃), while also adapting to the slow release characteristics of components caused by the dense fibrous structure of the stems, ensuring adsorption balance.
[0030] Detection of active ingredients in volatile extracts from the stems of Actinidia arguta var. arguta. GC-MS analysis conditions: The chromatographic column was an HP-5ms ultra-inert capillary column (30m × 0.25mm × 0.25μm); the carrier gas was high-purity helium, with a flow rate of 1.0mL / min. A temperature program was used: initial temperature of 35℃ for 2 min, then increased to 95℃ at 3℃ / min, then to 200℃ at 4℃ / min, and finally increased to 280℃ at 15℃ / min and held for 15 min to achieve effective separation of low, medium, and high boiling point components. Mass spectrometry conditions included an EI ion source with an electron energy of 70 eV, an ion source temperature of 230℃, and a scan range of m / z 40-550.
[0031] Identification results and key findings: The total ion chromatogram was processed using a chemical workstation, such as... Figure 1 As shown, qualitative analysis was performed by combining NIST17 mass spectrometry library search (matching degree ≥85%) with manual spectrum analysis, and relative quantification was performed by peak area normalization method.
[0032] The analysis results are shown in Tables 1 to 3. They clearly show that the relative content of trans-3-hexen-1-ol in the volatile components of the hardy kiwifruit stem is 50.11%, the relative content of 1-hexanol is 28.39%, and the sum of the relative contents of the two is 78.5%. This data is the first characteristic extract.
[0033] Table 1. Volatile components and relative contents (%) of hardy kiwifruit stems Table 2 is a continuation of Table 1. Table 3 is a continuation of Table 2. Example 2: Activity experiment of volatile active ingredient extract from the stem of Actinidia arguta var. arguta. Parallel samples prepared in the same batch as those used for GC-MS qualitative analysis (i.e., headspace vials pretreated and bottled using the same method) were sequentially extracted using the aforementioned HS-SPME extraction conditions (55℃, 60 min). After extraction, the SPME extraction head was immediately removed and inserted into a 200 μL microsample vial containing 150 μL of chromatographically pure dimethyl sulfoxide, ensuring the extraction head coating was completely submerged. The sample was allowed to stand for 10 minutes, with vortexing for 10 seconds every 2 minutes to fully desorb the adsorbed volatile components into the dimethyl sulfoxide, yielding the eluent, which is the mother liquor of the extract of volatile components from the stem of *Actinidia arguta*. This mother liquor was stored at -80℃ for later use.
[0034] Because the mother liquor was prepared using the same sample pretreatment, HS-SPME extraction, and desorption conditions as the qualitative analysis, and was used to enrich parallel samples from the same batch, and because the entire preparation process was completed rapidly under strict control, effectively avoiding component degradation or volatilization, it can be reasonably confirmed that the chemical composition of the obtained mother liquor is highly consistent with the extract of volatile stem components identified by direct analysis, and can be used for subsequent activity experiments.
[0035] 1) In vitro α-glucosidase inhibitory activity experiment of volatile component extracts from the stem of Actinidia arguta. In vitro α-glucosidase inhibitory activity was evaluated using the PNPG method. The volatile component extract from the stem of *Actinidia arguta* prepared in Example 1 was used as the test sample, and working solutions were diluted with phosphate-buffered saline (PBS, pH 6.8) to a series of concentrations: 1 mg / mL, 0.2 mg / mL, 0.05 mg / mL, 0.01 mg / mL, and 0.002 mg / mL. Acarbose was used as a positive control. The experimental results are as follows: Figure 2 As shown in Table 4, the volatile component extracts from the stems of Actinidia arguta exhibited concentration-dependent inhibition of α-glucosidase in the concentration range of 0.002–1 mg / mL. At a concentration of 1 mg / mL, the inhibition rate reached as high as 95.73%.
[0036] The half-maximal inhibitory concentration (IC50) of the extract against α-glucosidase was calculated using dose-response curves. 50 The concentration was 0.433 mg / mL, compared to the positive control drug acarbose (IC50). 50 The activity was comparable to that of 0.390 mg / mL, indicating that the extract possesses potent α-glucosidase inhibitory activity. This result demonstrates that the volatile component extract from the stem of Actinidia arguta provided in this invention is an effective α-glucosidase inhibitor, capable of exerting a hypoglycemic effect by inhibiting carbohydrate digestion, providing direct experimental evidence for its application in the preparation of hypoglycemic drugs.
[0037] Table 4. IC50 of volatile component extracts (AAS) from the stem of Actinidia arguta (hardy kiwifruit) 50 value 2) Cytotoxicity test of volatile component extracts from the stems of Actinidia arguta to L02 cells. To determine the safe dosage concentration for subsequent activity experiments, the effects of the volatile component extract (AAS) from the stem of Actinidia arguta (a hardy kiwifruit) and the positive control metformin (Met) on the viability of L02 cells (Cell Bank of the Chinese Academy of Sciences (Shanghai, China)) were evaluated using the CCK-8 assay. L02 cells were administered at a concentration of 1×10⁻⁶. 5 Cells were seeded at a density of 1 cell per well and treated with AAS and Met at concentrations of 25 μg / mL, 50 μg / mL, 100 μg / mL and 200 μg / mL, respectively, for 24 hours. Cell viability was then assessed using the CCK-8 assay.
[0038] Experimental results are as follows Figure 3 As shown: at a concentration of 0 μg / mL (normal control group), the survival rate of L02 cells treated with both Met and AAS was close to 100%. Within the concentration range of 25 μg / mL to 100 μg / mL, after 24 hours of AAS treatment, the cell survival rates remained at approximately 100%, 100%, and 95%, respectively, showing no significant difference from the normal control group. The cell survival rate of Met (positive control) remained at 105%–110% within this concentration range, demonstrating a certain cell proliferation-promoting effect. When the concentration was increased to 200 μg / mL, the cell survival rate of the AAS group remained at approximately 85%, and the survival rate of the Met group was approximately 105%, with neither showing significant cytotoxicity. These results indicate that the volatile component extract (AAS) from the stem of Actinidia arguta provided in this invention is non-toxic to L02 cells at concentrations ≤100 μg / mL and exhibits good cell compatibility. Even at a concentration increased to 200 μg / mL, no significant toxicity was observed, providing direct evidence for subsequent evaluation of its hypoglycemic activity within a safe concentration range.
[0039] 3) Establishment of an insulin-resistant L02 cell (IR-L02) model To evaluate the effect of the samples on improving insulin resistance, a stable in vitro screening model needs to be constructed first. In this embodiment, an insulin resistance model of normal human hepatocytes L02 was constructed using the insulin induction method.
[0040] Methods: L02 cells were inoculated at a rate of 1×10⁻⁶. 5 Seeding density of cells / well, using different concentrations of insulin 0mM, 10... -5 mM, 10 - 4 mM, 10 -3 mM, 10 -2The model was induced with mM medium for 24 hours, and glucose consumption was measured using a glucose assay kit to evaluate the model.
[0041] The results are as follows Figure 4 As shown, at 0mM, 10 -5 mM, 10 -4 At insulin concentrations of 10 mM, glucose consumption in L02 cells remained at a relatively high level of 6.0 mM–6.1 mM, with no significant difference between groups; when insulin concentration increased to 10 mM… -3 At mM, cellular glucose consumption decreased to 4.5 mM, a reduction of approximately 26.23% compared to the normal control group; when insulin concentration reached 10... -2 At 10 mM, cellular glucose consumption further decreased to 4.0 mM, a significant reduction of 34.43% compared to the normal control group (6.1 mM), indicating the most significant inhibitory effect. These results demonstrate that using 10 mM... -2 Insulin at a concentration of mM can successfully induce a stable IR-L02 cell model. This model can effectively simulate the characteristics of decreased glucose uptake capacity in cells under insulin resistance and can be used for screening subsequent samples to improve insulin resistance activity.
[0042] 4) The effect of volatile component extracts from the stems of Actinidia arguta on improving the insulin-resistant L02 (IR-L02) cell model. In the IR-L02 cell model, the effects of the extract on glucose consumption and liver glycogen synthesis were comprehensively evaluated to elucidate its role in improving insulin resistance.
[0043] The established IR-L02 cell model included a normal control group, a model control group, a drug-treated group (containing extracts of volatile active ingredients from the stems of Actinidia arguta at concentrations of 25 μg / mL, 50 μg / mL, and 100 μg / mL), and a positive control group. Twenty-four hours after drug intervention, the residual glucose in the cell supernatant and the intracellular glycogen content were measured.
[0044] The effect on promoting glucose consumption: results are as follows Figure 5 As shown, compared with the normal group cells (5.56±0.26mM), the glucose consumption of the IR-L02 model group (3.41±0.24mM) was significantly reduced, indicating that the glucose absorption and utilization capacity of IR-L02 cells was significantly impaired.
[0045] Compared with the model group (3.41±0.24mM), the effects of different concentrations of the extract of volatile components from the stem of Actinidia arguta on glucose consumption in IR-L02 cells varied: the extract at a concentration of 25 μg / mL increased glucose consumption in IR-L02 cells by approximately 0.22 times; the extract at a concentration of 50 μg / mL increased glucose consumption by approximately 0.36 times; and the extract at a concentration of 100 μg / mL increased glucose consumption by approximately 0.57 times.
[0046] At a concentration of 100 μg / mL, the glucose consumption of IR-L02 cells in the extract-treated group was the highest (5.47 ± 0.09 mM), close to that of the normal group (5.56 ± 0.26 mM); the glucose consumption in the 25 μg / mL concentration group was the lowest (4.43 ± 0.21 mM), a 0.22-fold increase compared to the model group. Meanwhile, the glucose consumption in the positive control metformin (Met) group also showed an increasing trend with increasing concentration, similar to the improvement effect of the extract group.
[0047] Compared with the model group, when the extract concentration was 25 μg / mL, the glucose consumption of IR-L02 cells was slightly increased; when the concentration increased to 50 μg / mL, the consumption further increased; and when the concentration reached 100 μg / mL, the consumption increased significantly, approaching the level of the normal group. This indicates that the improving effect of the extract is dose-dependent, with more stable activity and greater application potential. These results demonstrate that the extract of this invention can promote glucose consumption in IR-L02 cells in a dose-dependent manner. At a concentration of 100 μg / mL, glucose consumption recovered to near-normal levels, an increase of approximately 0.57 times compared to the model group, effectively improving cellular glucose uptake and utilization disorders caused by insulin resistance.
[0048] Promoting effect on liver glycogen synthesis The results are as follows Figure 6 The effect of the volatile component extract (AAS) from the stem of Actinidia arguta on glycogen content in IR-L02 cells is shown. Compared with the normal control group (15.55±0.66µg / mg prot), the glycogen content in the model group (9.01±0.34 µg / mg prot) was significantly reduced, indicating that the glycogen synthesis capacity of IR-L02 cells was significantly impaired under insulin resistance.
[0049] Intervention with volatile component extracts from the stems of Actinidia arguta resulted in a significant dose-dependent increase in glycogen synthesis in IR-L02 cells: at a concentration of 25 µg / mL, the glycogen content in the extract group (8.91 ± 0.40 µg / mg prot) was not significantly different from that in the model group; when the concentration increased to 50 µg / mL, the glycogen content in the extract group increased to 12.14 ± 0.49 µg / mg prot, which was higher than that in the model group; when the concentration reached 100 µg / mL, the glycogen content in the extract group (15.51 ± 0.22 µg / mg prot) was close to that of the normal control group (15.55 ± 0.66 µg / mg prot).
[0050] Compared with the model group, at a concentration of 100 µg / mL, the extract of volatile components from the stem of Actinidia arguta increased glycogen synthesis in IR-L02 cells by approximately 0.62 times. The glycogen content in the positive control metformin (Met) group also showed an increasing trend with increasing concentration, reaching 15.06 ± 0.49 µg / mg prot at 100 µg / mL, which was similar to the improvement effect of the extract group.
[0051] In summary, the volatile component extract from the stem of *Actinidia arguta* can regulate hepatic glucose metabolism through a dual mechanism of promoting glucose consumption in IR-L02 cells and enhancing glycogen synthesis, thereby improving peripheral glucose utilization, alleviating insulin resistance, and lowering blood glucose. These results collectively confirm that the volatile component extract from the stem of *Actinidia arguta* can synergistically improve insulin resistance and exert a hypoglycemic effect through the dual mechanisms of "promoting peripheral glucose consumption" and "increasing hepatic glycogen synthesis."
[0052] The above are merely preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. An extract of volatile active ingredients from the stem of Actinidia arguta (hardy kiwifruit) with anti-diabetic effects, characterized in that, The volatile active ingredients in the hardy kiwifruit stem source are released by salting out with sodium chloride, and then obtained by headspace solid-phase microextraction using a DVB / CAR / PDMS three-phase extraction head; the mass ratio of sodium chloride to the hardy kiwifruit stem source is 1~4:1~3. The headspace solid-phase microextraction was performed at a temperature of 50℃~60℃ for 60min~70min.
2. The extract of volatile active ingredients from the stem of Actinidia arguta (hardy kiwifruit) with anti-diabetic effects according to claim 1, characterized in that, The extract of volatile active ingredients from the stem of Actinidia arguta contains 50.11% trans-3-hexen-1-ol and 28.39% 1-hexanol.
3. The extract of volatile active ingredients from the stem of Actinidia arguta (hardy kiwifruit) with anti-diabetic effects according to claim 1, characterized in that, The hardy kiwifruit stem source refers to the sample with a particle size ≤1mm obtained by quick-freezing and grinding the stem source with liquid nitrogen.
4. The extract of volatile active ingredients from the stem of Actinidia arguta (hardy kiwifruit) with anti-diabetic effects according to claim 3, characterized in that, The stem source has a moisture content of 70% to 80%.
5. The use of the extract of volatile active ingredients from the stem of Actinidia arguta as described in claim 1 in the preparation of a drug for relieving and improving insulin resistance.
6. The application according to claim 5, characterized in that, The drug contains an extract of volatile active ingredients derived from the stem of Actinidia arguta, with a content of not less than 100 μg / mL.
7. The use of the extract of volatile active ingredients from the stem of Actinidia arguta as described in claim 1 in the preparation of a drug for inhibiting α-glucosidase.
8. The application according to claim 7, characterized in that, The drug contains an extract of volatile active ingredients derived from the stem of Actinidia arguta, with a content of not less than 1 mg / mL.
9. The application according to any one of claims 5 to 8, characterized in that, The extract of volatile active ingredients from the stem of Actinidia arguta is desorbed into a solvent to obtain an eluent; or the extract of volatile active ingredients from the stem of Actinidia arguta is adsorbed onto a carrier to obtain the drug.